Prescription rate of GLP-1s based on diagnosis Source: Piaopiao, L et al JAMA Network Open October 31, 2025 Research published in JAMA Network Open evaluated trends in prescribing of GLP-1 agents from 2010 through the end of 2024 using the Cosmos data warehouse, which has at least some medical records for 300 million Americans
Research has shown that hyperglycemia inhibits the expression of SIRT1 in islet -cells, leading to decreased levels of the antioxidant enzyme GPX4 and increased expression of the ferroptosis-related protein TFR1
The medicine slows gastric emptying what used to feel like a normal portion may now feel like overeating, and overeating while on a GLP-1 medicine can produce predictable nausea and discomfort
I.JeongY
Haddad M, Stewart J, Xie P, et al
Gastrointestinal side effects are the most frequently reported adverse reactions with GLP-1 receptor agonists, particularly during the initial weeks of treatment or following dose escalation